Athira Pharma Overview
- Year Founded
-
2011

- Status
-
Public
- Employees
-
67

- Stock Symbol
-
ATHA

- Share Price
-
$0.47
- (As of Friday Closing)
Athira Pharma General Information
Description
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
Contact Information
Website
www.athira.comCorporate Office
- 18706 North Creek Parkway
- Suite 104
- Bothell, WA 98011
- United States
Corporate Office
- 18706 North Creek Parkway
- Suite 104
- Bothell, WA 98011
- United States
Athira Pharma Stock Performance
As of 14-Feb-2025, Athira Pharma’s stock price is $0.47. Its current market cap is $18.1M with 38.7M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$0.47 | $0.44 | $0.41 - $4.30 | $18.1M | 38.7M | 281K | -$2.84 |
Athira Pharma Financials Summary
As of 30-Sep-2024, Athira Pharma has a trailing 12-month revenue of null.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | (73,218) | (78,803) | (99,055) | 252,897 |
Revenue | 0 | 0 | 0 | 0 |
EBITDA | (108,250) | (116,703) | (94,794) | (54,374) |
Net Income | (109,222) | (117,672) | (95,639) | (54,853) |
Total Assets | 86,246 | 160,245 | 258,153 | 332,008 |
Total Debt | 1,314 | 1,585 | 1,911 | 1,920 |
Athira Pharma Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Athira Pharma Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Athira Pharma Comparisons
Industry
Financing
Details
Athira Pharma Competitors (15)
One of Athira Pharma’s 15 competitors is Cassava Sciences, a Formerly VC-backed company based in Austin, TX.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Cassava Sciences | Formerly VC-backed | Austin, TX | ||||
Quince Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
Cognition Therapeutics | Formerly VC-backed | New York, NY | ||||
Alzheon | Venture Capital-Backed | Framingham, MA | ||||
Pharmatrophix | Venture Capital-Backed | Menlo Park, CA |
Athira Pharma Patents
Athira Pharma Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2023263997-A1 | Methods of treating neuroinflammatory conditions | Pending | 04-May-2022 | ||
AU-2023265053-A1 | Methods of treating neuropathies. | Pending | 04-May-2022 | ||
EP-4482510-A1 | Methods of treating covid-related disorders | Pending | 23-Feb-2022 | ||
CA-3240896-A1 | Uses of bicyclic compounds for the treatment of diseases | Pending | 17-Dec-2021 | ||
EP-4448100-A1 | Uses of bicyclic compounds for the treatment of diseases | Pending | 17-Dec-2021 | A61K31/519 |
Athira Pharma Signals
Athira Pharma Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Athira Pharma ESG
Risk Overview
Risk Rating
Updated October, 01, 2023
25.56 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,842
Rank
Percentile

Pharmaceuticals
Industry
of 898
Rank
Percentile

Biotechnology
Subindustry
of 402
Rank
Percentile

Athira Pharma FAQs
-
When was Athira Pharma founded?
Athira Pharma was founded in 2011.
-
Where is Athira Pharma headquartered?
Athira Pharma is headquartered in Bothell, WA.
-
What is the size of Athira Pharma?
Athira Pharma has 67 total employees.
-
What industry is Athira Pharma in?
Athira Pharma’s primary industry is Drug Discovery.
-
Is Athira Pharma a private or public company?
Athira Pharma is a Public company.
-
What is Athira Pharma’s stock symbol?
The ticker symbol for Athira Pharma is ATHA.
-
What is the current stock price of Athira Pharma?
As of 14-Feb-2025 the stock price of Athira Pharma is $0.47.
-
What is the current market cap of Athira Pharma?
The current market capitalization of Athira Pharma is $18.1M.
-
Who are Athira Pharma’s competitors?
Cassava Sciences, Quince Therapeutics, Cognition Therapeutics, Alzheon, and Pharmatrophix are some of the 15 competitors of Athira Pharma.
-
What is Athira Pharma’s annual earnings per share (EPS)?
Athira Pharma’s EPS for 12 months was -$2.84.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »